Tianjin Medical University Cancer Institute and Hospital: Pancreatic Neoplasms trials
The registry lists 25 Pancreatic Neoplasms studies with Tianjin Medical University Cancer Institute and Hospital as lead sponsor. 17 are open to participants now and 0 have results posted.
Phase 1 4Phase 2 16Phase 3 3Phase 4 1No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic CancerNot yet recruitingNCT07828756Phase 2
- Five-Element Music Therapy for Psychological Distress in Pancreatic Cancer ChemotherapyNot yet recruitingNCT07796906Not applicable
- Baduanjin for Quality of Life in Pancreatic Cancer ChemotherapyNot yet recruitingNCT07791550Not applicable
- Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer SurgeryRecruitingNCT07632118Phase 3
- QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic CancerRecruitingNCT06951997Phase 2
- A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic CancerRecruitingNCT06944106Phase 2
- AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic CancerNot yet recruitingNCT06938503Phase 2
- A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic CancerRecruitingNCT06760364Phase 1
- Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic CancerRecruitingNCT06454448Phase 1/2
- Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic CancerNot yet recruitingNCT06409429Phase 2/3
- Nimotuzumab Plus AG in Pancreatic Cancer With Liver MetastasisRecruitingNCT06405685Phase 2
- Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II StudyRecruitingNCT06404840Phase 2
- Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic CancerNot yet recruitingNCT06259058Phase 1/2
- The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic CancerRecruitingNCT06208436
- A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal AdenocarcinomaRecruitingNCT05997147
- Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic CancerRecruitingNCT05679050Phase 2
- Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic CancerRecruitingNCT05035147Phase 4
- Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic CancerCompletedNCT05908747Phase 2
- Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard ChemotherapyStatus unknownNCT05627427Phase 2
- Early Detection of Pancreatic CancerStatus unknownNCT05596435
- Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic CancerStatus unknownNCT04814485Phase 2
- Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic CancerStatus unknownNCT04808687Phase 2
- Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic CancerStatus unknownNCT03236883Phase 1
- A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic CancerStatus unknownNCT02863367Phase 2
- Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic CancerWithdrawnNCT01598584Phase 2/3